Literature DB >> 29526732

High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.

Laura Paleari1, Jürgen Burhenne2, Johanna Weiss2, Sebastian Foersch3, Wilfried Roth3, Andrea Parodi4, Michael Gnant5, Thomas Bachleitner-Hofmann5, Dominique Scherer6, Cornelia M Ulrich7, Borut Stabuc8, Matteo Puntoni9, Gianni Coccia4, Marilena Petrera10, Walter-Emil Haefeli2, Andrea DeCensi11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29526732      PMCID： PMC6002843          DOI： 10.1053/j.gastro.2017.12.040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  8 in total

1.  Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment.

Authors:  Michael Pollak
Journal:  Nat Med       Date:  2014-06       Impact factor: 53.440

2.  Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.

Authors:  Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Michiko Sugiyama; Eiji Sakai; Takashi Uchiyama; Kaori Suzuki; Hiroshi Iida; Yasunari Sakamoto; Kyoko Yoneda; Tomoko Koide; Chikako Tokoro; Yasunobu Abe; Masahiko Inamori; Hitoshi Nakagama; Atsushi Nakajima
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-01

Review 3.  Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

Authors:  Andrea Decensi; Matteo Puntoni; Pamela Goodwin; Massimiliano Cazzaniga; Alessandra Gennari; Bernardo Bonanni; Sara Gandini
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-12

Review 4.  Metformin in cancer: translational challenges.

Authors:  Ryan J O Dowling; Saroj Niraula; Vuk Stambolic; Pamela J Goodwin
Journal:  J Mol Endocrinol       Date:  2012-03-29       Impact factor: 5.098

5.  Accumulation of metformin by tissues of the normal and diabetic mouse.

Authors:  C Wilcock; C J Bailey
Journal:  Xenobiotica       Date:  1994-01       Impact factor: 1.908

6.  Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.

Authors:  Takuma Higurashi; Kunihiro Hosono; Hirokazu Takahashi; Yasuhiko Komiya; Shotaro Umezawa; Eiji Sakai; Takashi Uchiyama; Leo Taniguchi; Yasuo Hata; Shiori Uchiyama; Akiko Hattori; Hajime Nagase; Takaomi Kessoku; Jun Arimoto; Nobuyuki Matsuhashi; Yoshiaki Inayama; Shoji Yamanaka; Masataka Taguri; Atsushi Nakajima
Journal:  Lancet Oncol       Date:  2016-03-03       Impact factor: 41.316

Review 7.  Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.

Authors:  Zhi-Jiang Zhang; Zhi-Jie Zheng; Haidong Kan; Yiqing Song; Wei Cui; Genming Zhao; Kevin E Kip
Journal:  Diabetes Care       Date:  2011-10       Impact factor: 19.112

Review 8.  Metformin and the gastrointestinal tract.

Authors:  Laura J McCreight; Clifford J Bailey; Ewan R Pearson
Journal:  Diabetologia       Date:  2016-01-16       Impact factor: 10.122
  8 in total
  13 in total

1.  Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis.

Authors:  Xiaowen Huang; Xialu Hong; Jilin Wang; Tiantian Sun; TaChung Yu; Yanan Yu; Jingyuan Fang; Hua Xiong
Journal:  EBioMedicine       Date:  2020-10-09       Impact factor: 8.143

Review 2.  Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention.

Authors:  Mingyang Song; Andrew T Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2018-07-18       Impact factor: 11.382

3.  Metformin inhibition of colorectal cancer cell migration is associated with rebuilt adherens junctions and FAK downregulation.

Authors:  Gastón Amable; Eduardo Martínez-León; María Elisa Picco; Sergio I Nemirovsky; Enrique Rozengurt; Osvaldo Rey
Journal:  J Cell Physiol       Date:  2020-04-02       Impact factor: 6.384

4.  Metformin use and the Risk of Gastrointestinal Malignancies in Diabetic Populations: A Meta-Analysis.

Authors:  Gil Hevroni; Samara Skwiersky; Angelina Zhyvotovska; Samy I McFarlane
Journal:  Int J Clin Endocrinol Metab       Date:  2020-12-26

5.  Determination of metformin bio-distribution by LC-MS/MS in mice treated with a clinically relevant paradigm.

Authors:  Kiran Chaudhari; Jianmei Wang; Yong Xu; Ali Winters; Linshu Wang; Xiaowei Dong; Eric Y Cheng; Ran Liu; Shao-Hua Yang
Journal:  PLoS One       Date:  2020-06-11       Impact factor: 3.240

Review 6.  Mechanisms of action of metformin with special reference to cardiovascular protection.

Authors:  Alexey V Zilov; Sulaf Ibrahim Abdelaziz; Afaf AlShammary; Ali Al Zahrani; Ashraf Amir; Samir Helmy Assaad Khalil; Kerstin Brand; Nabil Elkafrawy; Ahmed A K Hassoun; Adel Jahed; Nadim Jarrah; Sanaa Mrabeti; Imran Paruk
Journal:  Diabetes Metab Res Rev       Date:  2019-07-24       Impact factor: 4.876

Review 7.  The Hormetic Effect of Metformin: "Less Is More"?

Authors:  Isabella Panfoli; Alessandra Puddu; Nadia Bertola; Silvia Ravera; Davide Maggi
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

8.  Does the antidiabetic drug metformin affect embryo development and the health of brown trout (Salmo trutta f. fario)?

Authors:  Stefanie Jacob; Andreas Dötsch; Sarah Knoll; Heinz-R Köhler; Eike Rogall; Dominic Stoll; Selina Tisler; Carolin Huhn; Thomas Schwartz; Christian Zwiener; Rita Triebskorn
Journal:  Environ Sci Eur       Date:  2018-12-07       Impact factor: 5.893

Review 9.  Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment.

Authors:  Min Li; Xiaoying Li; Huijie Zhang; Yan Lu
Journal:  Front Physiol       Date:  2018-07-31       Impact factor: 4.566

10.  Modulating the Distant Spreading of Patient-Derived Colorectal Cancer Cells via Aspirin and Metformin.

Authors:  Gemma Palazzolo; Hilaria Mollica; Valeria Lusi; Mariangela Rutigliani; Martina Di Francesco; Rui Cruz Pereira; Marco Filauro; Laura Paleari; Andrea DeCensi; Paolo Decuzzi
Journal:  Transl Oncol       Date:  2020-04-01       Impact factor: 4.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.